Dual-Phase PET-CT to Differentiate [18F]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in Patients with Prostate Cancer

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Oprea Lager, Daniela E ^a   Vincent, Andrew D ^b   van Moorselaar, Reindert J A ^a   Gerritsen, Winald R ^a,c   van den Eertwegh, Alfons J M ^a   Eriksson, Jonas ^a,d   Boellaard, Ronald ^a   Hoekstra, Otto S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROMETHYLCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LYMPH NODE HYPERPLASIA; LYMPHOMA; MALE; PELVIS LYMPH NODE; PROSTATE CANCER; RADIODIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREND STUDY;

AGED; AGED, 80 AND OVER; CHOLINE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; ROC CURVE;

EID: 84868335538     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048430     Document Type: Article

References (38)

1. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, et al. (2001) Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42: 1805-1814.
2. Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN, (2007) Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 37: 420-428.
3. Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S, (2011) Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol 80: e50-56.
4. Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, et al. (2006) Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imaging Biol 8: 43-48.
5. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, et al. (2011) The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 59: 51-60.
6. Jadvar H, (2011) Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate and 18F- or 11C-choline. J Nucl Med 52: 81-89.
7. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, et al. (2008) Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 113: 895-904.
8. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, et al. (2010) 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254: 925-933.
9. Hara T, Kosaka N, Kishi H, (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39: 990-995.
10. Igerc I, Kohlfürst S, Gallowitsch HJ, Matschnig S, Kresnik E, et al. (2008) The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging 35: 976-983.
11. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, et al. (2012) 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 15(1): 45-55.
12. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, et al. (2006) Imaging prostate cancer with 11C-choline. J Nucl Med 47(8): 1249-1254.
13. Schillaci O, Calabria F, Tavolozza M, Cicciò C, Carlani M, et al. (2010) 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 31: 39-45.
14. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE, (2002) Pharmacokinetics and radation dosimetry of 18F-fluorocholine. J Nucl Med 43: 92-96.
15. Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN, (2006) Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 47: 262-269.
16. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, et al. (2002) Comparison of [18F]Fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168: 273-280.
17. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, et al. (2006) [18F]-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33: 1387-1398.
18. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. (2011) EAU guidelines on prostate cancer. Part1:screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1): 61-71.
19. Egevad L, Mazzucchelli R, Montironi R, (2012) Implications of the International Society of Urological Pathology Modified Gleason Grading System. Arch Pathol Lab Med 136(4): 426-434.
20. Inoue S, Shiina H, Arichi N, Mitsui Y, Hiraoka T, et al. (2011) Identification of lymphatic pathway involved in the spreading of prostate cancer by fluorescence navigation approach with intraoperatively injected indocyanine green. Can Urol Assoc J 5: 254-259.
21. Tokuda Y, Carlino LJ, Gopalan A, Tickoo SK, Kaag MG, et al. (2010) Prostate cancer topography and patterns of lymph node metastasis. Am J Surg Pathol 34: 1862-1867.
22. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, et al. (2007) Sentinel lymph node dissection for prostate cancer: experience with more than 1000 patients. J Urol 177: 916-920.
23. Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJ, (1996) Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional T1-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 167: 1503-1507.
24. Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, et al. (2011) Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 13(2): 352-361.
25. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, et al. (2001) Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61: 110-117.
26. Iwata R, Pascali C, Bogni A, Furumoto S, Terasaki K, et al. (2002) [18F]fluoromethyl triflate, a novel and reactive [18F]fluoromethylating agent: preparation and application to the on-column preparation of [18F]fluorocholine. Appl Radiat Isot 57: 347-352.
27. Windhorst AD, ter Linden T, de Nooij A, Keus JF, Buijs FL, et al. (2001) A complete, multipurpose, low cost, fully automated and GMP compliant radiosynthesis system. J Labelled Cpd Radiopharm 44: 1052-1054.
28. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, et al. (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37: 181-200.
29. Cheebsumon P, van Velden FH, Yaqub M, Frings V, de Langen AJ, et al. (2011) Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment. J Nucl Med 52: 1550-1558.
30. Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, et al. (2010) Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med 51: 1870-1877.
31. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, et al. (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63: 387-395.
32. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, et al. (2009) Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 50: 1394-1400.
33. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, et al. (2008) The detection rate of [11C]Choline- PET/CT depends on the serum PSAvalue in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35: 18-23.
34. Fuccio C, Castellucci P, Schiavina R, Santi I, Allegri V, et al. (2010) Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 24: 485-492.
35. Breeuwsma AJ, Pruim J, van den Bergh AC, Leliveld AM, Nijman RJ, et al. (2010) Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using 11C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 77: 60-64.
36. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, et al. (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100: 786-793.
37. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, et al. (2007) Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 34: 45-53.
38. Hartemink KJ, Muller S, Smulders YM, Petrousjka van den Tol M, Comans EF, (2010) Fluorodeoxyglucose F18(FDG)-probe guided biopsy. Ned Tijdschr Geneeskd. 2010 154: A1884.